Dr.Reddy’s Laboratories Ltd (NYSE:RDY) – Research analysts at Jefferies Financial Group raised their FY2019 earnings estimates for shares of Dr.Reddy’s Laboratories in a note issued to investors on Monday, February 4th. Jefferies Financial Group analyst P. Nahar now expects that the company will post earnings per share of $1.52 for the year, up from their prior estimate of $1.38. Jefferies Financial Group also issued estimates for Dr.Reddy’s Laboratories’ FY2020 earnings at $1.98 EPS and FY2021 earnings at $2.29 EPS.

Several other brokerages have also issued reports on RDY. Zacks Investment Research lowered Dr.Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, January 18th. TheStreet raised Dr.Reddy’s Laboratories from a “c+” rating to a “b” rating in a research report on Friday, February 1st. ValuEngine upgraded Dr.Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research note on Friday, October 12th. CL King upgraded Dr.Reddy’s Laboratories from a “neutral” rating to a “buy” rating in a research note on Monday. Finally, Citigroup downgraded Dr.Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research note on Thursday, January 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. Dr.Reddy’s Laboratories has a consensus rating of “Hold” and a consensus price target of $43.00.

Shares of NYSE:RDY opened at $39.37 on Thursday. Dr.Reddy’s Laboratories has a 52-week low of $28.13 and a 52-week high of $40.20. The company has a market capitalization of $6.62 billion, a PE ratio of 38.98 and a beta of 0.16. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.62 and a quick ratio of 1.17.

Several institutional investors have recently bought and sold shares of the stock. Commonwealth Bank of Australia boosted its stake in Dr.Reddy’s Laboratories by 1.9% during the 3rd quarter. Commonwealth Bank of Australia now owns 1,793,360 shares of the company’s stock valued at $62,047,000 after purchasing an additional 33,166 shares during the last quarter. BlackRock Inc. boosted its stake in Dr.Reddy’s Laboratories by 11.3% during the 3rd quarter. BlackRock Inc. now owns 1,735,559 shares of the company’s stock valued at $60,049,000 after purchasing an additional 175,791 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Dr.Reddy’s Laboratories by 9.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 918,416 shares of the company’s stock valued at $31,792,000 after purchasing an additional 82,589 shares during the last quarter. Advisors Asset Management Inc. boosted its stake in Dr.Reddy’s Laboratories by 29,814.7% during the 2nd quarter. Advisors Asset Management Inc. now owns 863,638 shares of the company’s stock valued at $119,000 after purchasing an additional 860,751 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Dr.Reddy’s Laboratories by 36.5% during the 3rd quarter. Renaissance Technologies LLC now owns 783,300 shares of the company’s stock valued at $27,102,000 after purchasing an additional 209,490 shares during the last quarter. Institutional investors own 11.31% of the company’s stock.

Dr.Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Further Reading: What is a put option?

Earnings History and Estimates for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.